That Bcr-TMP inhibits MYB activity in AML cells is further supported by the down-regulation of several direct MYB target genes already after two hours of treatment, while MYB expression itself was not decreased due to the short incubation time. The gene discussed is MYB; the disease is acute myeloid leukemia.